Question Bank › Mid-ramp quarter: contribution has started but t

Mid-ramp quarter: contribution has started but the period only caught part of it

Calls Tested
421
Answered YES
20
Hit Rate
4.8%
rare by design

Vanda Pharmaceuticals Inc. (VNDA) — this company's answers

NO on the Q4 2021 call 2022-02-23 F
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes an identifiable piece of new business activity that has already started contributing partway through the reported period or is starting right now, and makes clear that the reported results captured only a partial, early slice of it, with the fuller run-rate arriving over the next few quarters as a matter of timing. Let's examine the transcript. The call is Q4 2021 earnings. Management discusses several things: HETLIOZ, Fanapt, tradipitant, etc. Key points: - HETLIOZ: They mention strong interest, but payer denials led to net decline. They discuss efforts to resolve payer challenges, particularly with Medicaid. They mention that they have made progress in the past quarter with state Medicaid programs, and that 10 states have revised criteria. They also mention that they are developing strategies for Medicare and commercial plans. However, this is about resolving payer challenges, not about a new business activity that has started contributing. It's about overcoming obstacles to existing business. - HETLIOZ for Smith-Magenis Syndrome (SMS): They launched HETLIOZ and HETLIOZ LQ for SMS. More than 50 patients with SMS are on treatment and more are awaiting payer approval. They are working with advocacy and DTC campaigns. This is a new indication launch. The launch has started, with 50 patients on treatment. But is this described as a partial early slice? They say "More than 50 patients with SMS are currently on treatment and more are awaiting payer approval." That suggests it's early, but they don't explicitly say that the reported results captured only a fraction of the potential. They also mention that they are working to increase awareness. However, the revenue from SMS is likely small relative to overall. They don't quantify the contribution. They also mention that payer reception for SMS has been more positive. But the question is whether management describes this as a new contributor that is already live and will ramp up over the next few quarters as a matter of timing. They do say "We are in the early stages of commercial launch for HETLIOZ in SMS" and that they expect growth tied to the continued launch. In the guidance, they say the upper end of HETLIOZ net product sales guidance assumes growth tied to the continued launch of HETLIOZ in SMS. So they are treating it as a contributor that is ramping.

← Back to the full VNDA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe an identifiable piece of new business activity that has ALREADY STARTED CONTRIBUTING PARTWAY THROUGH THE REPORTED PERIOD OR IS STARTING RIGHT NOW — and make clear that the reported results captured only a PARTIAL, EARLY SLICE of it, with the fuller run-rate arriving over the next few quarters as a matter of timing rather than as a matter of winning anything further? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent timing story with all three of the following present: (1) A NAMEABLE NEW CONTRIBUTOR THAT IS ALREADY LIVE OR JUST GOING LIVE. Management identifies specific business that recently began or is beginning now — for example, a contract or program whose deliveries or billings recently started; a facility, location, line, or capacity that recently opened or is opening; a product, service, or offering that recently launched and is now selling; a customer or group of customers recently onboarded and now ramping; an acquisition recently closed and now contributing; or newly added capability now taking on its first real volume. The contributor must be described as actually transacting or commencing — real revenue, orders, shipments, output, or activity happening — not as pipeline, negotiation, or plan. (2) THE REPORTED PERIOD CAUGHT ONLY PART OF IT, AND MANAGEMENT SAYS SO. Management conveys, directly or plainly in substance, that the just-reported results include only a fraction of this contributor's normal level — because it started mid-period, is still ramping toward its intended level, or its costs arrived ahead of its revenue — so the printed numbers understate the level the business is already operating at or stepping to. (3) THE FULLER CONTRIBUTION IS A TIMING MATTER, NOT A WINNING MATTER. Management discusses the path to the fuller level in execution terms — ramp pace, onboarding, production schedules, utilization building, quarters until full contribution — with the remaining uncertainty being how fast, not whether the business exists. Management should treat this arriving contribution as meaningful to the company's trajectory, not as a minor housekeeping item. Answer NO if the new activity is only planned, signed-but-not-started, contingent on approvals or financing, or still pipeline. NO if the contributor is already fully reflected in results with no meaningful further phase-in ahead. NO if the forward story rests mainly on market recovery, demand strength, or hoped-for wins rather than on the phase-in of activity already begun. NO if the ramp described is routine, immaterial, or the company's ordinary ongoing cadence that management does not treat as changing its level of business. NO if management is chiefly explaining delays, shortfalls, or problems with a previously promised ramp. NO if the timing story appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
GPRE Green Plains Inc. Q4 2023 2024-02-07 F
TEL TE Connectivity Ltd. Q4 2023 2023-11-01 B
AFL Aflac Incorporated Q2 2023 2023-08-02 C+
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
WHF WhiteHorse Finance, Inc. Q1 2022 2022-05-10 B+
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
MAS Masco Corporation Q3 2018 2018-10-30 C
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
ACHC Acadia Healthcare Company, Inc. Q4 2017 2018-02-22 C+
HTLF Heartland Financial USA, Inc. Q3 2017 2017-10-30 B+
MXL MaxLinear, Inc. Q2 2017 2017-08-08 C+
FLEX Flex Ltd. Q1 2018 2017-07-28 F
LEA Lear Corporation Q2 2017 2017-07-26 B+
DAN Dana Incorporated Q1 2017 2017-05-02 B
SHOO Steven Madden, Ltd. Q1 2017 2017-04-21 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
WTS Watts Water Technologies, Inc. Q4 2016 2017-02-10 B

How the model reasoned

SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.

More from the question bank

Ecosystem forming: independent outsiders areOperating without a netCall runs ahead of the accountsCustomers eating the frictionBuying its own future outputBetting the balance sheet on one live opportAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.